Risk factors associated with competing mortality among patients with head and neck cancer in Japan

2015 ◽  
Vol 136 (3) ◽  
pp. 325-329 ◽  
Author(s):  
Yukinori Takenaka ◽  
Toshimichi Yasui ◽  
Keisuke Enomoto ◽  
Haruka Miyabe ◽  
Natsue Morizane ◽  
...  
2006 ◽  
Vol 132 (8) ◽  
pp. 874
Author(s):  
M. Schultzel ◽  
G. Robins-Sadler ◽  
K. L. Clark ◽  
M. Loscalzo ◽  
R. Weisman ◽  
...  

Head & Neck ◽  
2020 ◽  
Vol 42 (9) ◽  
pp. 2571-2580
Author(s):  
Yumiko Kawashita ◽  
Shimpei Morimoto ◽  
Kensuke Tashiro ◽  
Sakiko Soutome ◽  
Masako Yoshimatsu ◽  
...  

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 223-223
Author(s):  
Navika Shukla ◽  
Anirudh Saraswathula ◽  
Saad A. Khan ◽  
Vasu Divi

223 Background: Despite the recent introduction of the CMS metric, OP-35, which tracks 30-day inpatient admissions and ED visits after outpatient chemotherapy administration, the risk factors driving acute care utilization (ACU) in the head and neck cancer treatment setting are not yet well understood. Further characterization of these risk factors could allow for improved care quality and reduce preventable inpatient and ED admissions. Methods: This was a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked cancer registry-claims database. The study cohort consisted of patients aged 66 years or older diagnosed with head and neck cancer between 2004-2015 who received outpatient chemotherapy within the first two years after diagnosis. Multivariable logistic regression modeling was utilized to characterize the risk factors associated with an inpatient or ED admission within 30 days after receiving chemotherapy. Results: Of the 2,236 eligible patients, 735 (32.9%) had at least one inpatient or ED admission within 30 days of receiving outpatient chemotherapy. On multivariable analysis, cancer of the oral cavity [odds ratio (OR) 1.43; 95% confidence interval (CI) 1.04-1.96] and oropharynx/hypopharynx [OR 1.34; 95% CI 1.06-1.70] were associated with an increased odds of ACU. Other factors associated with ACU included NCI comorbidity index [OR 1.10; 95% CI 1.03-1.18], prior ACU [OR 1.06; 95% CI 1.02-1.09], second cycle of chemotherapy relative to the first cycle [OR 0.38, 95% CI 0.29-0.50], and third or greater cycle of chemotherapy [OR 0.17; 95% CI 0.13-0.21]. Certain chemotherapeutic agents also modified risk: use of an angiogenesis inhibitor [OR 0.18; 95% CI 0.06-0.45], alkylating agent [OR 1.24; 95% 1.01-1.53], plant alkaloid [OR 1.63; 95% CI 1.25-2.10], or antimetabolite [OR 2.69; 95% CI 1.78-4.09]. The most common admission diagnosis was pain (n = 243; 33.1%) followed by dehydration (n = 167; 22.7%). Conclusions: Multiple clinical variables modify risk of acute care utilization after outpatient chemotherapy in the head and neck cancer setting, providing several potential avenues of intervention for providers.


2010 ◽  
Vol 28 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Loren K. Mell ◽  
James J. Dignam ◽  
Joseph K. Salama ◽  
Ezra E.W. Cohen ◽  
Blase N. Polite ◽  
...  

Purpose Death from noncancer causes (competing mortality) is an important event in head and neck cancer, but studies identifying predictors of this event are lacking. We sought to identify predictors of competing mortality and develop a risk stratification model for competing events. Patients and Methods Cohort study of 479 patients with stage III to IV carcinoma of the head and neck diagnosed between August 1993 and November 2004. Patients were treated on consecutive prospective clinical trials involving organ-preserving chemoradiotherapy and surgery. We used multivariable competing risks regression models to analyze factors associated with the cumulative incidence of competing mortality, locoregional and distant failure, and second malignancies as first events. Results Median follow-up was 52 months median for survivors. The 5-year cumulative incidence of competing mortality was 19.6% (95% CI, 15.8 to 23.4). On multivariable analysis, competing mortality was associated with female sex (hazard ratio [HR], 1.72; 95% CI, 1.13 to 2.63), increasing age (HR, 1.30; 95% CI, 1.04 to 1.62), increasing Charlson Comorbidity Index (HR, 1.24; 95% CI, 1.05 to 1.47), decreasing body mass index (HR, 0.33; 95% CI, 0.13 to 0.84), and decreasing distance traveled to the treating center (HR, 0.65; 95% CI, 0.44 to 0.98). Patients with zero, one, two, and ≥ three risk factors had 5-year competing mortality of 8.9% (95% CI, 3.0% to 14.8%), 12.4% (95% CI, 7.0% to 17.8%), 22.1% (95% CI, 14.5% to 29.7%), and 39.3% (95% CI, 28.6% to 50.1%), respectively. Conclusion Competing mortality in advanced head and neck cancer is associated with several demographic and health status characteristics. Analyses of risk factors for competing mortality may be useful in outcomes reporting and designing clinical trials.


Author(s):  
Jagtar Singh ◽  
Ramya Ramamoorthi ◽  
Siddhartha Baxi ◽  
Rama` Jayaraj ◽  
Mahiban Thomas

Sign in / Sign up

Export Citation Format

Share Document